Business Wire

Brigade-M3 European Acquisition Corp. Redemption notice

25.5.2023 18:30:00 EEST | Business Wire | Press release

Share

Brigade-M3 European Acquisition Corp. (the "Company"), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V. ("Euronext Amsterdam"), today announces that it will not conclude a business combination before its business combination deadline on 14 June 2023 (the "Business Combination Deadline"). Therefore, the board of directors of the Company (the "Board") resolved to initiate the redemption of all listed unit shares and ordinary shares in the share capital of Company (the "Units" and "Ordinary Shares", respectively) following the Business Combination Deadline in accordance with the terms and conditions for the redemption of the Units and Ordinary Shares in the Company's articles of association and as disclosed in the Company's IPO prospectus dated 8 December 2021 (the "Prospectus").

Since the Company became listed on Euronext Amsterdam on 14 December 2021, the Company has been searching for a target to consummate a business combination. During this period, the Company has investigated various potential targets and held explorative talks with a selection of them, but despite extensive efforts to date, the Company has not been able to find a suitable target for a business combination. As the Business Combination Deadline is forthcoming, the Board deems it highly unlikely that the Company will be able to complete a business combination before the Business Combination Deadline and, therefore, the Board has decided to initiate the redemption of the Units and Ordinary Shares following the Business Combination Deadline. In accordance with the disclosure in the Prospectus, the Company will procure that the amount held in the Escrow Account will be returned to the holders of Units and Ordinary Shares as promptly as reasonably possible but not more than ten trading days after the Business Combination Deadline.

Holders of Units and Ordinary Shares will receive redemption proceeds from the Escrow Account through payment by the Company's Listing Agent, at an expected price per Unit or Ordinary Share of $10.20 plus accrued interest (this amount comprises of (i) $10.00 initial subscription price; (ii) $0.20 escrow overfunding by the Company's sponsor; and (iii) the pro rata part of the accrued interest on the Escrow Account). Holders of Units and Ordinary Shares will receive this payment in exchange for the delivery of the Units or Ordinary Shares via the shareholder’s intermediary to the Listing Agent. As a result of the Company not completing a business combination before the Business Combination Deadline, the public warrants and the sponsor warrants will automatically expire without value on the Business Combination Deadline in line with the terms and conditions of the warrants and the disclosure in the Prospectus. There will be no distribution of proceeds or otherwise from the Escrow Account with respect to the public warrants or the sponsor warrants.

Indicative timetable

The timetable below sets forth certain expected key dates for the redemption of the Units and Ordinary Shares.

Event

   

Date

Business Combination Deadline

   

14 June 2023

Last trading day

14 June 2023

Expiration of sponsor warrants and public warrants

   

15 June 2023

Record date for the redemption of Units and Ordinary Shares

   

16 June 2023

Payment of redemption proceeds

   

20 June 2023

Redemption of Units and Ordinary Shares

   

21 June 2023

Post-Redemption

Following the Business Combination Deadline and the redemption of the Units and Ordinary Shares (and the expiration of the public warrants and the sponsor warrants), the only outstanding securities of the Company will be the sponsor shares. The Board intends to seek sponsor shareholder approval to adopt amended and restated memorandum and articles of association in order to facilitate the re-purposing and continuation of the Company, subject to additional capital being committed by the sponsor for such purpose. The redeemed Units and Ordinary Shares will be held in treasury by the Company for the purpose of re-allocating such Units and Ordinary Shares in the future.

IMPORTANT INFORMATION

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

DISCLAIMER

This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public for securities in any jurisdiction.

In the EEA, this announcement is only directed at persons who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended. In the United Kingdom, this announcement is directed only at “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU) No 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ENQUIRIES
Brigade-M3 European Acquisition Corp.
c/o Brigade Capital Management, LP
399 Park Avenue, 16th Floor
New York, NY 10022
Email: BrigadeM3EAC@brigadecapital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release

Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release

For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye